MichaelJOvermanMD

Oncology • Houston, TX

Gastrointestinal Cancer, Hematologic Oncology

Associate Professor at MD Anderson Cancer Center

Join to view full profile

Dr. Overman is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Overman's full profile

Already have an account?

Office
1515 Holcombe Blvd
Houston, TX 77030
Phone+1 713-792-6161

Education & Training

University of Texas Health Science Center at Houston/M D Anderson Cancer CenterFellowship, Hematology and Medical Oncology, 2004 - 2007
Los Angeles County-Harbor-UCLA Medical CenterResidency, Internal Medicine, 2000 - 2003
Johns Hopkins University School of MedicineClass of 2000

Certifications & Licensure

CA State Medical License 2002 - Present
FL State Medical License 2021 - Present
AZ State Medical License 2023 - 2026
GA State Medical License 2023 - 2026
OK State Medical License 2020 - 2026
TN State Medical License 2023 - 2026
TX State Medical License 2004 - 2026
WA State Medical License 2023 - 2026
AL State Medical License 2023 - 2025
LA State Medical License 2023 - 2025
MS State Medical License 2023 - 2025
American Board of Internal Medicine Medical Oncology
Join now to see all

Clinical Trials

Azacitidine and CAPOX in Metastatic Colorectal Cancer Start of enrollment: 2010 Aug 01
Completed
Phase 1, Phase 2
Bevacizumab, Capecitabine, and Oxaliplatin in Treating Advanced Small Intestinal or Ampulla of Vater Adenocarcinoma Start of enrollment: 2011 May 06
Completed
Phase 2
Irinotecan Plus Brivanib in Metastatic Colorectal Cancer (CRC) Enriched for Elevated Levels of Plasma FGF Start of enrollment: 2011 Aug 01
Terminated
Phase 2
A Study of Nivolumab Alone or Nivolumab Combination Therapy in Colon Cancer That Has Come Back or Has Spread Start of enrollment: 2014 Mar 12
Active, not recruiting
Phase 2
Personalized Peptide Vaccine in Treating Patients With Advanced Pancreatic Cancer or Colorectal Cancer Start of enrollment: 2016 May 11
Recruiting
Phase 1
Tremelimumab and Durvalumab in Treating Patients With Colorectal Cancer With Liver Metastases That Can Be Removed by Surgery Start of enrollment: 2016 Jul 28
Completed
Phase 1
Pembrolizumab in Treating Patients With Small Bowel Adenocarcinoma That is Metastatic or Locally Advanced and Cannot Be Removed by Surgery Start of enrollment: 2017 Mar 24
Active, not recruiting
Phase 2
Study of Tilsotolimod in Combination With Nivolumab and Ipilimumab for the Treatment of Solid Tumors (ILLUMINATE-206) Start of enrollment: 2019 Oct 29
Active, not recruiting
Phase 2
Pembrolizumab Before Surgery for the Treatment of Mismatch Repair Deficient Locally Advanced Solid Cancers Start of enrollment: 2019 Sep 17
Active, not recruiting
Phase 2
Fecal Microbiota Transplant and Re-introduction of Anti-PD-1 Therapy (Pembrolizumab or Nivolumab) for the Treatment of Metastatic Colorectal Cancer in Anti-PD-1 Non-responders Start of enrollment: 2021 Feb 22
Active, not recruiting
Phase 2
Pevonedistat and Pembrolizumab for the Treatment of dMMR/MSI-H Metastatic or Locally Advanced Unresectable Solid Tumor Start of enrollment: 2021 Mar 29
Terminated
Phase 1, Phase 2
The Phoenix Trial: Phase II Trial of Cemiplimab for the Non-operative Management of Localized dMMR Colon Cancer Start of enrollment: 2024 May 20
Recruiting
Phase 2
Roles: Contact, Principal Investigator
Join now to see all

Publications & Presentations

PubMed

Mutational and co-mutational landscape of early onset colorectal cancer.
Jumanah Yousef Alshenaifi, Guglielmo Vetere, Giulia Maddalena, Mahmoud Yousef, Michael G White
Biomarkers. 2025-01-09
Physical Activity and Dexamethasone for Cancer-Related Fatigue: A Preliminary Placebo-Controlled, Randomized, Double-Blind Trial.
Sriram Yennurajalingam, Vicente Valero, Brandon G Smalgo, Michael J Overman, Aravind Dasari
Journal of the National Comprehensive Cancer Network. 2025-01-07
Trastuzumab Plus Pertuzumab Versus Cetuximab Plus Irinotecan in Patients WithWild-Type, HER2-Positive, Metastatic Colorectal Cancer (S1613): A Randomized Phase II Trial.
Kanwal Pratap Singh Raghav, Katherine A Guthrie, Benjamin Tan Jr, Crystal S Denlinger, Marwan Fakih
Journal of Clinical Oncology. 2025-01-06

Journal Articles

Assessment of Image-Guided Intratumoral Delivery of Immunotherapeutics in Patients with Cancer
Michael J Overman, Adi Diab, Patrick Hwu, JAMA Network Open
Anti-EGFR Resistant Clones Decay Exponentially After Progression: Implications for Anti-EGFR Re-Challenge
B Kee, N Garg, M J Overman, V K Morris, B Johnson, J Wu, J H Strickler, S Kopetz, X Liu, D S Hong, Annals of Oncology

Lectures

How to Approach Biomarker Testing for Colorectal Cancer in 2019
ASCO Annual Meeting 2019 - Chicago, IL - 6/2/2019
A priori filtering of post-operative (post-op) circulating tumor DNA (ctDNA) to predict recurrence in post-metastasectomy colorectal cancer patients (CRC pts) without ...
2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018
Safety, efficacy and pharmacodynamics (PD) of MEDI9447 (oleclumab) alone or in combination with durvalumab in advanced colorectal cancer (CRC) or pancreatic cancer (pa...
2018 ASCO Annual Meeting - Chicago, Illinois - 06/3/2018
Optimal Approach to Colorectal Cancer With Deficient Mismatch Repair (dMMR)
2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018
Join now to see all

Other